Source: Google NewsPublished on 2023-05-25
Related Articles:
- The road ahead: 2022 January 20, 2022 # # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s. It is an exercise in managing expectations as well as discussing what research events are scheduled for the next year so that we can keep…
- The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
- HanAll Biopharma and Daewoong Pharmaceutical Enter into Co ... - BioSpace May 25, 2023 HanAll Biopharma and Daewoong Pharmaceutical Enter into Co ... BioSpace
- HanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmaceuticals to Develop Therapy for Parkinson's Disease May 25, 2023 HanAll Biopharma and Daewoong Pharmaceutical will co-develop NurrOn Pharmaceuticals' novel investigational compounds, including its lead asset ATH-399A, targeting Nurr1 for the treatment of Parkinson's disease (PD), as well as other neurodegenerative disorders Phase 1 clinical trial is...
- HanAll Biopharma, Daewoong Pharmaceutical to co-develop Parkinson's drug with NurrOn - KBR May 25, 2023 HanAll Biopharma, Daewoong Pharmaceutical to co-develop Parkinson's drug with NurrOn KBR
- HanAll Biopharma, Daewoong sign deal for Parkinson's therapy - Pharmaceutical Technology May 26, 2023 HanAll Biopharma, Daewoong sign deal for Parkinson's therapy Pharmaceutical Technology
- The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
- Daewoong, Hanall invest in NurrOn Pharmaceuticals for collaboration in US - Korea Biomedical Review July 29, 2021 Daewoong, Hanall invest in NurrOn Pharmaceuticals for collaboration in US Korea Biomedical Review
- HanAll, Daewoong Developing Parkinson's Disease Treatment with ... - BusinessKorea May 26, 2023 HanAll, Daewoong Developing Parkinson's Disease Treatment with ... BusinessKorea
- Monthly Research Review – July 2021 July 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during July 2021. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
- ADepTing to the UCB-Novartis deal December 6, 2021 # # # # Alpha synuclein has long been viewed at “Public enemy #1” by the Parkinson’s research community. This sticky, abundant protein starts to cluster (or aggregate) in Parkinson’s. There have been several attempts to reduce levels of the protein floating around outside of cells (using “immunotherapy” approaches) But now clinical research is ramping up to determine if reducing…
- Prevail lands on a Lilly pad December 15, 2020 # # # # 2020 has been a dreadful year for most of the world – burdened by the outbreak and consequences of COVID-19. Despite this, there has been a steady stream of biotech acquisitions related to Parkinson’s which have helped to keep morale high in the PD research community. In October alone, we saw the Portuguese pharmaceutical company Bial…
- UCB at ANN looks A-OK April 26, 2021 # # # # Alpha synuclein is one of the most common proteins in our brains and it has long been associated with Parkinson’s. The protein appears to clump together forming dense clusters ( or “aggregates“) in the Parkinsonian brain, and this may be related to the progressive neurodegeneration. Researchers have been desperately seeking small molecules that will break up…
- 2020: Year in Review January 1, 2021 # # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies…
- Theravance Biopharma to Present New Ampreloxetine Data in Neurogenic Orthostatic Hypotension at the 33rd International Symposium on the Autonomic Nervous System - PR Newswire October 25, 2022 Theravance Biopharma to Present New Ampreloxetine Data in Neurogenic Orthostatic Hypotension at the 33rd International Symposium on the Autonomic Nervous System PR Newswire
- GB Sciences Granted US Patent for Cannabinoid-based Formulations for Parkinson’s May 7, 2020 GB Sciences has been granted a patent from the U.S. Patent and Trademark Office (USPTO) covering the use of its proprietary cannabinoid-containing complex mixtures for treating Parkinson’s disease, the company announced. GB Sciences is creating a pipeline of new medicines based on cannabinoids, the pharmacologically active compounds that give the cannabis plant its medical and recreational properties. The patent — number 10,653,640…
- Shkreli wants back into biopharma with blockchain bet - FierceBiotech July 26, 2022 Shkreli wants back into biopharma with blockchain bet FierceBiotech
- XWPharma Names Michael M. Morrissey, PhD to Board of DirectorsAppointment Adds Senior Biopharma Operational Expertise to Board Oversight as Company Advances its Pipeline of Novel CNS Therapeutics in Research and Clinical Development - BioSpace December 16, 2020 XWPharma Names Michael M. Morrissey, PhD to Board of DirectorsAppointment Adds Senior Biopharma Operational Expertise to Board Oversight as Company Advances its Pipeline of Novel CNS Therapeutics in Research and Clinical Development BioSpace
- Emulate enhances tech aimed at supporting disease research and drug development - BioPharma-Reporter.com November 22, 2021 Emulate enhances tech aimed at supporting disease research and drug development BioPharma-Reporter.com
- GSK and University of Oxford launch new institute, embracing advanced technologies for drug discovery - BioPharma-Reporter.com December 2, 2021 GSK and University of Oxford launch new institute, embracing advanced technologies for drug discovery BioPharma-Reporter.com
- 4D Pharma to trial LBPs in patients with Parkinson's disease: 'We are continuing to expand clinical pathways for the microbiome field' - BioPharma-Reporter.com February 22, 2022 4D Pharma to trial LBPs in patients with Parkinson's disease: 'We are continuing to expand clinical pathways for the microbiome field' BioPharma-Reporter.com4D pharma Announces FDA Clearance of IND Application for Live Biotherapeutics MRx0005 and MRx0029 for the Treatment of Parkinson's Disease BioSpace4D pharma receives US regulatory green light for phase I trial of Parkinson"s disease candidates Proactive Investors USA4D Pharma Shares Rise as…
- Lilly to acquire gene therapy specialist, Prevail Therapeutics, in a deal worth US$1.04bn - BioPharma-Reporter.com December 15, 2020 Lilly to acquire gene therapy specialist, Prevail Therapeutics, in a deal worth US$1.04bn BioPharma-Reporter.com